Comparative Pharmacology
Head-to-head clinical analysis: ZANTAC 150 versus ZANTAC IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ZANTAC 150 versus ZANTAC IN PLASTIC CONTAINER.
ZANTAC 150 vs ZANTAC IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive histamine H2-receptor antagonist that inhibits basal and stimulated gastric acid secretion by blocking H2 receptors on parietal cells in the stomach.
Competitive antagonist of histamine H2 receptors on gastric parietal cells, reducing basal and stimulated gastric acid secretion.
150 mg orally twice daily or 300 mg orally once daily at bedtime.
150 mg orally twice daily or 50 mg intravenously every 6 to 8 hours.
None Documented
None Documented
2.5 hours (range 1.5-3.5 h); prolonged in renal impairment (creatinine clearance <50 mL/min: 4-8 h).
Terminal elimination half-life: 2.5–3 hours; prolonged to 4–5 hours in elderly or moderate renal impairment; accumulates in severe renal failure (CrCl <10 mL/min).
Renal (70% unchanged via tubular secretion), biliary (30% as metabolites and unchanged drug).
Renal: 70% (unchanged drug); Hepatic metabolism: 30% (minor N-oxide, S-oxide, and desmethyl metabolites); Biliary/fecal: negligible.
Category C
Category C
H2 Antagonist
H2 Antagonist